Oxytocin (OXT), synthesized in the hypothalamic paraventricular nucleus (PVN) and then released into different brain areas, may play a crucial role in various behaviors and neuropsychiatric disorders, including depression. Testosterone has been proposed by clinical studies to have the opposite effect of oxytocin in these disorders. We began by studying, in the postmortem hypothalamus of fifteen patients with mood disorders and fifteen matched controls, the expression of OXT in the PVN by means of immunocytochemistry (ICC) and the co-localization of OXT and androgen receptor (AR) by means of double labeling ICC. Subsequently, the regulatory effect of AR on OXT gene expression was studied in vitro. We found a higher expression of PVN OXT in the mood disorder patients than in the control subjects, and observed a clear co-localization of AR in OXT-expressing neurons, both in the cytoplasm and in the nucleus. In addition, a significant decrease in OXT-mRNA levels was observed after pre-incubation of the SK-N-SH cells with testosterone. A further potential androgen-responsive element in the human OXT gene promotor was revealed by electrophoretic mobility shift assays and cotransfections in neuroblastoma cells. Finally, in vitro studies demonstrated that AR mediated the down-regulation of OXT gene expression. These results suggest that the fact that OXT and testosterone appear to have opposite effects in neuropsychiatric disorders might be based upon a direct inhibition of AR on OXT transcription, which may provide a novel target for therapeutic strategies in depression.
INTRODUCTION
The neuropeptide oxytocin (OXT) is synthesized in the hypothalamic paraventricular nucleus (PVN) and supraoptic nucleus (SON). When released from the neurohypophysis it may act as a neurohormone and it thus plays a role in uterine contractions and milk ejection during parturition and lactation (Carson et al, 2013) . In recent decades, however, PVN OXT being synaptically released into different brain areas and playing a central role as a neuromodulator, has drawn increasing attention (Knobloch et al, 2012) . Central effects of OXT include affective social behaviors, such as maternal care and pair bonding (Smith et al, 2010) , the attenuation of fear and of the stress response (Quirin et al, 2011) , and the modulation of the symptoms of psychiatric disorders such as major depressive disorder (MDD) and bipolar disorder (BD) (Cochran et al, 2013) . The observations of the social and/or clinical effects of OXT have been generally performed by intranasal OXT administration. However, the belief that all effects of intranasal OXT can be explained by a direct OXT action on brain systems has been challenged (Leng and Ludwig, 2016) . In addition, the literature tends to remain equivocal on the direction of OXT changes in depression. For instance, both enhanced (Heinrichs and Domes, 2008; Turan et al, 2013) and weakened (Ozsoy et al, 2009 ) serum OXT levels have been reported in mood disorders. These considerations render it crucial to do postmortem brain research on the OXT system in clinically and neuropathologically well-characterized patients with mood disorders. Although we had observed increased numbers of OXT-expressing neurons in the hypothalamic PVN in depression in a previous relatively small study (Purba et al, 1996) , we needed to confirm this observation in a larger and independent brain sample, and we had to subsequently elucidate the mechanism of how OXT expression is regulated by testosterone.
A number of studies have pointed to the involvement of the steroid receptor family in the regulation of the activity of stress-related neuropeptide neurons in the hypothalamic PVN (Bao et al, 2006; Murakami et al, 2011; Watts, 2005) , which might play an important role in the pathogenesis of mood disorders. Indeed, the human OXT promoter was found to be up-regulated by estrogens, when ER was present (Richard and Zingg, 1990) . However, although a study by Zhou et al showed that OXT-expressing neurons in a particular part of the rat PVN, ie the ventral zone of the medial parvocellular part of the PVN, co-express androgen receptor (AR) (Zhou et al, 1994) , an other study claimed that rat PVN lacked AR (Bingaman et al, 1994) . In addition, we found clear AR expression in the human PVN (Bao et al, 2006; Fernándezguasti et al, 2000) . It was recently proposed that there were opposing effects of OXT and testosterone in cognitive and behavioral functions and in various neuropsychiatric disorders, such as autism, schizophrenia and depression (Crespi, 2015) , which makes the topic of a potential role of androgens in the regulation of OXT expression in human even more intriguing.
In the present study we therefore investigated, first in postmortem human brain tissue, the PVN OXT expression in depression and the possible presence of co-localization of the AR in OXT-immunoreactive neurons in the PVN. After we were able to confirm, in the largest sample to date, the presence of a larger amount of PVN OXT expression in depression patients and observed a clear co-localization of nuclear AR in OXT-immunoreactive neurons, we investigated the regulation of testosterone on OXT gene expression via AR as a nuclear transcriptional factor, and subsequently observed an inhibiting effect of AR on human OXT gene expression.
MATERIALS AND METHODS

Part 1: Immunohistochemistry in Human Hypothalamus
Postmortem brain material was obtained from the Netherlands Brain Bank (director Dr Inge Huitinga) following permission for a brain autopsy and the use of the brain material and clinical data for research purposes. The Diagnostic and Statistical Manual of Mental Disorders (DSM)-III-R/DSM-IV) criteria were used for the diagnosis of MDD or BD at any time during life. In total, hypothalamic material of 15 mood disorder patients (nine MDD, six BD) and fifteen matched control subjects was studied. The absence of neuropathological changes in all these subjects was confirmed by systematic neuropathology (van de Nes et al, 1998) . Detailed clinico-pathological information and P-values of the matched parameter are given in Supplementary Table S1 .
The hypothalami were dissected at autopsy and fixed in 0.1 M phosphate buffered 4% w/v formaldehyde (pH7.2) for 1-2 months. Tissues were dehydrated in graded ethanol, embedded in paraffin and serially cut into sections (6 μm) on a Leitz microtome and stored at room temperature. To localize the borders of the PVN, thionine staining was performed on every 100th section throughout the hypothalamus. The rostral and caudal borders of the OXT-PVN were later determined by immunocytochemical staining of OXT in every 100th section, and the beginning and end of the OXT-PVN were defined as the sections where no OXT cells were present.
Immunocytochemistry of OXT-immunoreactivity in the hypothalamic PVN. Sections were incubated at 4°C overnight with the OXT antibody (1 : 800, OT-A-I-28, a kind gift from Dr F.W. van Leeuwen, who obtained it from Dr A. Hou Yu). The next day, the sections were incubated at room temperature with a biotinylated anti-mouse antibody (1 : 400, BA-1000, Vector Laboratories, USA) for 1 h and stained with DAB-Ni substrate solutions (Sigma, Zwijndrecht, the Netherlands) for 15 min. Double-labeling of AR and OXT in hypothalamic PVN. For each subject, double staining of AR and OXT in hypothalamic PVN was performed on the section which contained the highest level of OXT-immunoreactivity. Sections were microwaved for 2 × 5 min at 800 W in 0.05 M Tris-HCl (pH 9.0) to unmask antigens. The sections were incubated with the rabbit polyclonal AR antibody (1 : 800, ab74272, Abcam, USA) for 1 h, then kept at 4°C overnight. The next day, after rinsing with TBS, the sections were incubated with mouse monoclonal OXT antibody (1 : 800, OT-A-I-28, a kind gift from Dr F.W. van Leeuwen, who obtained it from Dr A. Hou Yu) for 1 h. After subsequent rinsing with TBS, the sections were incubated with biotinylated anti-rabbit antibody (1 : 400, BA-1000, Vector Laboratories) for 1 h, followed by the incubation of ABC solution for 1 h. After another rinse with TBS, the sections were stained red with Vector NovaRED Substrate Kit (SK-4800, Vector, USA) for 15 min. After another rinse with TBS, the sections were incubated with alkaline phosphatase anti-mouse antibody (1 : 200, 115-055-003, Jackson ImmunoResearch, USA), and stained blue with Vector Blue Substrate Kit (SK-5300, Vector, USA) for 25 min. Sections were then rinsed and cover-slipped using Kaiser's glycerin (Merck Chemicals, Germany).
Image analysis. Quantification of the integrated optical density (IOD) of the OXT-immunoreactive signal was performed as described in our previous study (Gao et al, 2012 ) with a minor modification, which can be found in Supplementary Materials and Methods. The total IOD of oxytocin-immunoreactivity as determined by computerassisted morphometry is not only an objective method but also less time-consuming than neuron-counting. In addition, the IOD shows a good positive correlation with neuroncounting, performed in the way we described previously (Fronczek et al, 2005) : for twenty-two sections of one patient and one control: rho = 0.799, po0.001.
Part 2: In Vitro Studies in Cell Lines
Immunofluorescence. Human neuroblastoma SK-N-SH cells (Bioleaf Company, China) were cultured according to an existing protocol (Smets et al, 1989) . After having been grown in 96-well plates for 48 h, SK-N-SH cells were incubated with either polyclonal rabbit anti-AR antibody (1 : 50, ab74272) or polyclonal rabbit anti-OXT antibody (ab2078, Abcam, USA) for 12 h at 4°C. After washing in PBS, the cells were incubated for 1 h with Alexa Fluor 488 goat anti-rabbit IgG (1 : 1000, Beyotime Biotechnology, China) and mounted in FluorSave reagent (Beyotime Biotechnology, China). Images were captured with NIS-Elements imaging software (Nikon, Japan).
Effect of testosterone on OXT-mRNA expression. Testosterone (T1500, Sigma, USA) was diluted in 100% chloroform
Androgen inhibits human oxytocin D Dai et al and used at a final concentration of 10 − 5 M in 0.001% chloroform. Estrogen receptor (ER) antagonist ICI 182 780 (1286650, Sigma, USA) was diluted in 100% DMSO and used at a final concentration of 10 − 7 M in 0.001% DMSO. SK-N-SH cells were grown in 6-well plates for 12 h until they were attached to the bottom. Media containing FBS were then replaced by charcoal stripped FBS (Hyclone, USA). Once grown to 70% confluency, the SK-N-SH cells were exposed to ICI 182 780 for 0.5 h, followed by the addition of 10 − 5 nM testosterone (final concentration in 2 ml cell media) for 24 h. Control cells were treated with the same content of chloroform and DMSO. Total RNA isolation and cDNA synthesis were performed as described earlier (Wang et al, 2008) . QPCR procedures are indicated in Supplementary Materials and Methods.
Electrophoretic mobility shift assay (EMSA). In order to determine whether the human OXT promoter region contains potential androgen responsive elements (AREs), the human OXT gene promoter region was scanned with AR matrix models in an online database (http://jaspar.genereg. net) region (the nucleotide sequences of OXT were provided by the National Center for Biotechnology Information database at http://www.ncbi.nlm.nih.gov/gene/5020). At position − 346 bp and +204 bp of the human OXT gene promoter, there were two sequences (called site A and site B, respectively in the present study) closely resembling an ARE (site A resemblance rate: 81.6%; site B resemblance rate: 82.3%; Figure 4a ). Probes were designed based on the two candidate AREs. Sequences are shown in Supplementary  Table S3 . Nuclear extracts were made from 293T cells transiently transfected with PSV-AR. After transfection, nuclear proteins were extracted and identified by western blot. The experimental procedures are indicated in Supplementary Materials and Methods.
OXT luciferase reporter plasmid construction. To generate the reporter plasmids, two fragments from the human OXT gene promoter sequence were amplified from genomic DNA from Hela cells by nested PCR:
-a full-length fragment (from − 533 bp to +235 bp) denoted OXTA, which contained both potential ARE sites A and site B. -a shorter fragment (from − 298 bp to +235 bp) denoted OXTAm, which did not contain ARE site A.
For a schematic representation see Figure 5a . Fragments were amplified by nested PCR (see primers in Supplementary Table S4 ) and cloned into PGL3 luciferase reporter basic vector (E1751, Promega, USA).
OXT promoter fragments and PGL3 basic vectors were double-digested with restriction enzyme Kpn I and Hind III, ligated by T4 ligase, and amplified through bacterial transformation. The constructs were named as POXTA (containing OXTA) and POXTAm (containing OXTAm). The presence of the inserts was confirmed by DNA sequencing. The PRL-CMV renilla luciferase reporter construct (E2261, Promega, USA) was used as an internal control for plasmid transfection efficiency.
AR-OXT promoter interaction assay. 293FT cells were co-transfected at 70% confluency with PSV-AR and with one of the OXT gene promoter plasmids (POXTA or POXTAm) and incubated for 24 h in media containing 10% charcoal stripped FBS. Subsequently, testosterone (10 − 5 nM) was added for 24 h. Cells were fixed with 1% formaldehyde and stopped by glycine (0.125 M).
Before proceeding to the immunoprecipitation, two validation experiments were performed to verify the successful transfection of PSV-AR and OXT gene promoter plasmids. First, a western blot was performed with the polyclonal AR antibody (1 : 200, ab74272) and a secondary anti-rabbit horseradish peroxidase antibody (1 : 1000, MR-M100, MRBiotech, China). Secondly, PCR was performed using primers named Primer A and Primer B, which were designed to amplify ARE site A and ARE site B respectively (primers are shown in Supplementary Table S5 ) for detection of ARE sites within POXTA and POXTAm transfected samples.
Next, immunoprecipitation was performed according to the instructions of the EZ-Magna ChIP A/G kit (17-10086, Millipore) . This involved incubation of the POXTA-and POXTAm-transfected isolates with 5 μg rabbit anti-AR polyclonal antibodies. As a specificity control, POXTA samples were also reacted with 1 μg rabbit IgG. Untransfected cells were collected to serve as negative controls. Immunoprecipitated DNA was amplified by PCR using Primer A and primer B, respectively. Amplification products were analyzed by 2% agarose gel electrophoresis.
Luciferase reporter assay using the human OXT promoter. Since both EMSA and the AR-OXT promoter interaction assay showed that site A was the ARE on the OXT promoter, we investigated, by means of luciferase reporter assay, the effect of testosterone combined with AR on the OXT promoter. Co-transfection of 293 FT cells was performed using lipo 2000 (11668-027, Invitrogen). Cells were incubated with transfection reagent and plasmids PSV-AR and POXTA, together with the pRL-CMV vector (E2261, Promega, USA) as the internal control for 24 h, followed by testosterone treatment (10 − 5 nM) in DMEM, which contained 10% Charcoal Stripped FBS (Hangzhou Sijiqing biotech, China) to ensure steroid-free culture conditions. Twenty-four hours after the treatments, luciferase activity was measured using the dual-luciferase assay according to the manufacturer's protocol (E2920, Promega, USA). Relative light units were measured using the Varioskan Flash Multimode Reader (5250040, Thermo).
Statistical analysis. Data were analyzed using SPSS software (version 23). A Shapiro-Wilk normality test confirmed that the data were normally distributed. Student's t-test was applied to compare the differences between the experimental group and the control group. Also, a multiple linear regression model was applied to verify whether PVN OXTimmunoreactivity was associated with mood disorders, taking into consideration confounding factors such as sex, age, or postmortem delay. The Mardia-Watson-Wheeler test (Watson, 1982) was used for group comparisons of circular data, including the clock time of death and the month of death. Po0.05 was considered to be significant.
Specificity of antibodies. Specificity of antibodies is indicated in Supplementary Materials and Methods.
RESULTS
Mood Disorder Patients had Significantly Higher PVN OXT-Immunoreactivity
The mood disorder group showed a larger amount of (44.1%) PVN OXT-immunoreactivity than the control group (p = 0.027, Figure 1 ). In addition, multiple linear regression analysis revealed that PVN OXT-immunoreactivity was significantly associated with mood disorder (β = 6.798, p = 0.039), while sex, age, postmortem delay, fixation time and brain weight did not show a significant effect on PVN OXT-immunoreactivity (p ⩾ 0.157). There was no significant difference in OXT-immunoreactivity between the MDD and the BD group (p = 0.584, Figure 1 ). It should be noted, however, that some confounding factors, such as sex ratio, were not well-matched for the subgroup comparison.
Co-Localization of AR and OXT-Expressing Neurons in the PVN
OXT-immunoreactivity in the hypothalamic PVN was only present in the cytoplasm and in fibers, while AR-immunoreactivity was found in the nuclei, cytoplasm and fibers of OXT-expressing neurons. Some OXT-immunoreactive neurons (blue cytoplasm) were clearly co-expressing nuclear AR-immunoreactivity (red) (Figure 2 ). (Figure 3a) . Significantly decreased OXT-mRNA levels were found after pre-incubation of the cells with the ER antagonist ICI 182 780 followed by testosterone (student's t-test, p = 0.05, Figure 3b ).
Testosterone Decreased OXT-mRNA In Vitro
SK-N-SH cells showed clear endogenously expressed ARimmunoreactivity and OXT-immunoreactivity
Identification of Potential Functional AREs in Human OXT Promotor
In the EMSA study, only probe A (site A) strongly bound to nuclear extracts from 293T cells transfected with PSV-AR, shown as the two shifted bands on top of the gel (Figure 4b) , which according to a previous study (Wilson and McPhaul, 1996) are AR variants of about 87 and 110 kd, respectively. A 200-fold excess of unlabeled probe A was sufficient to outcompete the specific interaction with labeled probe A, eliminating the shifted bands (Figure 4b ). Altogether with previous findings that these two bands may combine with other nuclear compounds acting as AR co-regulator (Bennett et al, 2010) , our data indicated that site A probably represents a functional ARE.
Co-transfection of 293FT cells with the AR-expression plasmids POXTA and POXTAm was proved by western blot detection of AR (Figure 5b , panel I) and PCR amplification of ARE sites A and B using Primer A and primer B respectively (Figure 5b, panel II) .
The enrichment of AR-binding site A was confirmed in the POXTA co-transfected cell lysates with the anti-AR antibody, followed by PCR amplification of Primer A, while the same isolates with nonspecific rabbit IgG failed to show the PCR product, as did the untransfected 293FT cell lysates with the same anti-AR antibody (Figure 5b ). Furthermore, POXTAm co-transfected cell lysates with the anti-AR antibody did not demonstrate PCR product when Primer B was used, which indicated that site B does not interact with AR in the OXT promoter region. Together, these observations showed that AR binds only to ARE site A.
AR Represses the OXT Promoter
To examine how androgens might modulate OXT gene expression through the potential ARE (site A), the luciferase reporter plasmid POXTA was transiently transfected into 293FT cells, with or without co-transfection of the human AR expression vector PSV-AR, followed by testosterone treatment. OXT promoter transcriptional luciferase activity presented a significant decrease when, compared to controls without PSV-AR, cells were co-transfected with PSV-AR. This procedure was followed by testosterone treatment (p = 0.0126, Figure 5c ). This led us to conclude that testosterone may inhibit OXT gene expression, via an interaction between AR and ARE.
DISCUSSION
The data from our largest series of postmortem material so far confirm the presence of more PVN OXT expression in mood disorder patients (Purba et al, 1996) , while the co-localization of AR in some of the human PVN OXT-immunoreactive neurons is a novel finding. The co-localization of AR, both in the cytoplasm and in the nucleus, in human PVN OXT neurons points to the possibility of a direct regulating role of androgens on PVN OXT gene expression.
OXT may contribute to symptoms of depression in different ways. OXT is a satiety hormone and the enhanced hypothalamic OXT levels we observed may thus be related to the eating disorders that often accompany depression (Baxter, 2016; Lawson et al, 2012; Wade et al, 2000) . On the other hand, OXT has generally been associated with enhanced pro-social behaviors and the administration of OXT was found to reduce the symptoms of depression and anxiety (Hofmann et al, 2015) . At first sight, our findings of a larger amount of PVN OXT-immunoreactivity and the elevated peripheral OXT levels (Purba et al, 1996; Turan et al, 2013) thus seem puzzling. However, it has been proposed that higher OXT expression in depression might reflect a compensatory role: it may alleviate depressive symptoms and anxiety (McQuaid et al, 2014) . Indeed, OXT and CRH have opposing effects: CRH stimulates adrenocorticotropic hormone and cortisol release, while OXT inhibits corticotropic function in humans (Legros, 2001 ). Alternatively, OXT may increase the salience of social stimuli, irrespective of whether these stimuli are positive or negative. In this wayalso depending on OXT receptor-related polymorphisms-OXT could be associated with greater sensitivity and susceptibility to disturbed social relations, depressive symptoms and suicidal ideation (McQuaid et al, 2016) .
The human OXT gene expression was found to be up-regulated by estrogens via ER (Richard and Zingg, 1990 ). In addition, also the androgen metabolite, ie 5α-androstane, 3β, 17β-diol (3β-diol), was found to be capable to up-regulate OXT expression via ERβ by combining it with a hormoneresponsive element in the rat OXT gene promoter (Hiroi et al, 2013; Sharma et al, 2012) . This is why we used the ER antagonist ICI 182 780 in our experiments. With the neuroblastoma cell line SK-N-SH, which had endogenous ER, AR and OXT expression, we observed now for the first time that testosterone induced decreased OXT-mRNA expression. It is of importance to note that changes (either larger or smaller) in AR expression in mood disorders do not necessarily have an a priori correlation to the changes in OXT, since there are numerous other factors, such as many neurotransmitters and ER, involved in the regulation of OXT expression. However, the hypothesis that AR might play a role in the higher OXT-immunoreactivity in mood disorders is not only supported by our molecular work that indicates a direct regulating role of AR on OXT gene expression, but also by the lower testosterone levels observed in elderly depressed males (Rizvi et al, 2010) and females (Yasui et al, 2012) .
One of the inherent potential confounding factors in any postmortem study is medication. However, we do not think that our main conclusions are confounded by antidepressants. Some previous studies have shown that there were no obvious changes in plasma OXT concentration during selective serotonin reuptake inhibitor (SSRI) or electroconvulsive therapy treatment of depressed patients (Keating et (Saatcioglu, 2011; Wilson and McPhaul, 1996) . Androgen inhibits human oxytocin D Dai et al obsessive-compulsive disorder patients (Humble et al, 2013) . In addition, Haloperidol, which had been given to one mood disorder patient and three controls in the present study, was found not to influence OXT release in rat (Uvnäsmoberg et al, 1992) . Moreover, although Lithium (You et al, 2001) and Valproate (Štefánik et al, 2015) are reported to increase OXT release in rats and to increase OXT mRNA expression in rat hypothalamic PVN and SON, the IOD of OXTimmunoreactivity of the mood disorder patients who had been administered these compounds (IOD: 24.41, 27.39, and 18.06) were fully within the range of the other mood disorder patients (from 16.06 to 40.91, mean value 24.02). Furthermore, a benzodiazepine, such as chlordiazepoxide, was shown to inhibit OXT release in response to noxious stimuli (Yagi and Onaka, 1996) , and chronic morphine treatment in rat inhibited OXT synthesis (Morris et al, 2010; You et al, 2001 ). In our study, more mood disorder patients (n = 9) than control subjects (n = 3) were given diazepines, and more mood disorder patients (n = 9) than control subjects (n = 3) were exposed to morphine. Had these compounds interfered with our measurements, then this would have led to an underestimation of the increased OXT-immunoreactivity levels observed in mood disorder patients.
We subsequently identified a specific ARE site in the human OXT promoter, which can, in principle, be located either upstream or downstream of the transcription start site of androgen responsive genes (Saatcioglu, 2011) . We focused on one potential ARE site (named site A in the present study), near the start site ATG, which is most likely involved in the regulation of OXT gene expression. We observed, by means of EMSA, that this ARE (site A) does indeed bind to AR nuclear extracts, as evidenced by two separated bands and consistent with a previous report of two AR isoforms (Saatcioglu, 2011; Wilson and McPhaul, 1996) . Human OXT promoter transcriptional activity showed a significant decrease following cotransfection with an AR-expression plasmid and testosterone treatment, which indicated that testosterone may suppress OXT expression. Evidence from a previous study indicates a clear interplay between AR and ER, which may be either competitive or antagonistic (Need et al, 2012) . Therefore, the blocking of ER with ICI 182 780 in our experiments might potentiate the inhibitory effect of AR on OXT expression in SK-N-SH cells. Our data offer the first evidence of a direct inhibiting effect of androgens on human OXT expression.
It is of interest to note that AR knock-out mice showed higher expression levels of OXT receptor (OXTR) in the hypothalamus than controls (Karlsson et al, 2016) , which is consistent with our present findings. These findings together indicate that testosterone may have additive effects on oxytocinergic function. It should be noted, however, that there are also data indicating that androgens do not influence the expression of OXTR (Filippi et al, 2002) . Whether OXTR may act as an additional potential target for androgen actions needs to be elucidated in the future.
In conjunction with data from others, androgens may thus participate in the regulation of OXT levels, either inhibiting directly via AR, or indirectly stimulating OXT expression through its metabolite via ER (see above), both in health and in disease. In conclusion, there is more hypothalamic PVN OXT expression in mood disorders and co-localization of AR in human OXT neurons. Our observation that OXT expression is regulated by a direct inhibitory effect of the AR on OXT transcription may be the basis for the opposing effects of OXT and testosterone in psychological functions and neuropsychiatric disorders as proposed in the literature (Crespi, 2015) .
